Tempest reports year end 2024 financial results and provides business update

• granted both orphan drug & fast track designations for amezalpat (tpst-1120) for the treatment of patients with hepatocellular carcinoma (hcc) • announced agreement with roche to support advancement of amezalpat combination therapy into first-line hcc pivotal trial • received fda “study may proceed” letter for phase 2 trial of tpst-1495 for the treatment of familial adenomatous polyposis (fap)
HCC Ratings Summary
HCC Quant Ranking